FAQ

ADR-529

Known as: ADR 529, ADR529 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1990-2006
024619902006

Related topics

Related topics

2 relations

Broader (2)

DexrazoxaneDexrazoxane hydrochloride

Related mentions per year

Related mentions per year

1990-2018
1990200020102020
ADR-529
Dexrazoxane
Dexrazoxane hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardiotoxicity in animals, and is recommended as a… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
1994
1994
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and…
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… (More)
Is this relevant?
1993
1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and…
The effect of the bisdioxopiperazine cardioprotector ICRF-187 (ADR-529, dexrazoxan) on drug-induced DNA damage and cytotoxicity… (More)
Is this relevant?
1992
1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must… (More)
Is this relevant?
1992
1992
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1992
1992
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529
The purpose of this study was to evaluate the optimal timing of ADR-529 administration to protect rats treated with doxorubicin… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
1992
1992
In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this… (More)
Is this relevant?
1992
1992
A Sensitive and Specific Procedure for Quantitation of ADR-529 in Biological Fluids by High-Performance Liquid Chromatography (HPLC) with Column Switching and Amperometric Detection
An HPLC method using electrochemical detection (ED) has been validated for the determination of ADR-529 in plasma and urine using… (More)
Is this relevant?
1990
1990
Effects of (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane (ADR-529) on iron-catalyzed lipid peroxidation.
ADR-529 [(+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane], a nonpolar, cyclic analogue of EDTA, protects against anthracycline… (More)
Is this relevant?
Review
1990
Review
1990
Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).
Anthracyclines are powerful anticancer drugs whose use is limited by the development of chronic cardiotoxicity. The… (More)
Is this relevant?